Day Zero Diagnostics announced that it received an $8.2 million award in optional stage funding from CARB-X. The infectious disease diagnostic developer received an initial $6.2 million CARB-X award in May 2020. CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, aims to accelerate early antibacterial R&D. This would address the rising global threat of drug-resistant […]
Genomics/Molecular Diagnostics
OraSure Technologies receives $8.6M contract to develop next-gen Ebola test
OraSure Technologies (Nasdaq:OSUR) announced today that received a government contract to develop a second-generation Ebola diagnostic. The Biomedical Advanced Research and Development Authority (BARDA) issued the company the $8.6 million contract. Bethlehem, Pennsylvania-based OraSure is to develop the test on its OraQuick testing platform. Its aim is to improve sensitivity, increase shelf life, introduce new […]
Merit Medical Systems launches soft tissue biopsy system
Merit Medical Systems (Nasdaq:MMSI) announced today that it launched the Temno Elite soft tissue biopsy system in the U.S. South Jordan, Utah-based Merit designed Temno Elite for use in various soft tissue locations. This includes the liver, lung, lymph nodes, kidney, and other soft tissue suspect lesions. The single-use device complements a broader portfolio, the […]
BD, CerTest launch monkeypox diagnostic for lab research in U.S.
BD (NYSE:BDX) and CerTest Biotec announced today that they made their monkeypox virus assay commercially available for global research. The companies made the diagnostic available outside of the U.S. for use in research applications by laboratories in July. The molecular polymerase chain reaction (PCR) assay is now available globally for research applications only. Franklin Lakes, New Jersey-based BD […]
Medtech executive convicted of COVID-19 tests fraud
A federal jury convicted the president of a medtech company — Arrayit — accused of participating in a scheme to mislead investors over COVID-19 tests. In June 2020, the U.S. Department of Justice (DOJ) charged Arrayit president March Schena for alleged involvement with fraudulent claims for allergy and COVID-19 testing. The charges alleged a scheme […]
European Commission blocks Illumina’s Grail acquisition, company to appeal
Illumina (Nasdaq:ILMN) announced today that the European Commission issued a decision prohibiting its planned acquisition of Grail. San Diego-based Illumina said it is reviewing the order and intends to appeal the decision. The new hurdle in Europe follows a recent ruling in the U.S. that favored the acquisition. An administrative law judge in the U.S. […]
Illumina clears antitrust hurdle related to merger with Grail
Illumina (Nasdaq:ILMN) announced today that an administrative law judge in the U.S. has rejected the Federal Trade Commission’s argument that the company’s $8 billion acquisition of Grail was anti-competitive. More than a year after the deal closed, Illumina is still keeping Grail operating as a separate internal entity under a European Commission order. An Illumina […]
BD, Accelerate Diagnostics partner on rapid antibiotic testing
BD (NYSE:BDX) announced that it entered into a worldwide commercial collaboration agreement with Accelerate Diagnostics (Nasdaq:AXDX). Under the agreement announced earlier this week, BD will offer Accelerate’s rapid testing products and services for antibiotic resistance and susceptibility. Results arrive in hours compared to between one and two days with some traditional laboratory methods. Anti-biotic-resistant infections […]
Nanopath raises $10M Series A for women’s health diagnostics
Nanopath announced that it closed a Series A funding round to support its biosensing platform for diagnostics. Cambridge, Massachusetts–based Nanopath intends to use the funds to back the development and commercialization of its platform that aims to transform how women’s pelvic and gynecologic infections are diagnosed. The company designed its novel approach to simultaneously characterize […]
BD, Labcorp collaborate on flow cytometry-based diagnostics
BD (NYSE:BDX) announced today that it entered into a collaboration with Labcorp (NYSE:LH) to develop diagnostics. The collaboration aims to create the framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases. Under the agreement, BD and Labcorp Drug Development will […]
Bio-Rad acquires Curiosity Diagnostics for up to $170M
Bio-Rad Laboratories (NYSE:BIO) announced that it agreed to acquire all outstanding shares of Curiosity Diagnostics. Hercules, California-based Bio-Rad bought Curiosity Diagnostics from Scope Fluidics, a Warsaw, Poland-based developer of technologies for the medical diagnostic and healthcare markets, for a total consideration of up to $170 million. The acquisition consists of approximately $100 million in cash, […]